Treatment outcome of children with acute lymphoblastic leukemia: the Tokyo Children’s Cancer Study Group (TCCSG) Study L04-16

Hiroyuki Takahashi, Ryosuke Kajiwara, Motohiro Kato, Daisuke Hasegawa, Daisuke Tomizawa, Yasushi Noguchi, Kazutoshi Koike, Daisuke Toyama, Hiromasa Yabe, Michiko Kajiwara, Junya Fujimura, Manabu Sotomatsu, Setsuo Ota, Miho Maeda, Hiroaki Goto, Yoko Kato, Tetsuya Mori, Takeshi Inukai, Hiroyuki Shimada, Keitaro FukushimaChitose Ogawa, Atsushi Makimoto, Takashi Fukushima, Kentaro Ohki, Katsuyoshi Koh, Nobutaka Kiyokawa, Atsushi Manabe, Akira Ohara

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The survival rate of children with acute lymphoblastic leukemia (ALL) has increased to approximately 90% after substantial progress in risk-oriented treatment strategies. Between 2005 and 2013, the Tokyo Children’s Cancer Study Group (TCCSG) conducted a risk-oriented, non-randomized study, L04-16. The principal aim of this study was to assemble background characteristics and treatment outcomes, and gather genetic information on leukemic cells under central diagnosis. This report outlines the background characteristics and treatment outcomes of 1033 children with ALL treated according to a TCCSG platform. The 5-year event-free and overall survival (OS) rates for all children were 78.1 ± 1.3 and 89.6 ± 1.0%, respectively. The OS rate was significantly higher in children with B-cell precursor (BCP)-ALL (91.9 ± 1.0%, n = 916) than in those with T-ALL (71.9 ± 4.3%, n = 117, p < 0.001). In univariate analysis for BCP-ALL, children aged 1–6 years (5y-OS: 94.2 ± 1.0%), with an initial white blood cell count of < 20,000/μL (94.0 ± 1.0%), high hyperdiploidy (95.4 ± 1.6%), ETV6-RUNX1 (97.4 ± 1.2%) or TCF3-PBX1 (96.9 ± 2.1%), and “Day8NoBlasts” (96.4 ± 1.1%) had the best outcomes. Genetic investigation revealed two novel fusion genes within this cohort: ETV6-ZNF385A and ZNF362-TCF4. Our study highlighted the clinical aspects of genomic features of ALL in Japanese children. We provide fundamental information for the further molecular investigation of this disease.

Original languageEnglish
Pages (from-to)98-108
Number of pages11
JournalInternational Journal of Hematology
Volume108
Issue number1
DOIs
Publication statusPublished - 2018 Jul 1

Fingerprint

Tokyo
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Neoplasms
B-Lymphoid Precursor Cells
Survival Rate
Polyploidy
Leukocyte Count
Disease-Free Survival

Keywords

  • Acute lymphoblastic leukemia
  • Childhood leukemia
  • Clinical trial
  • Novel fusion genes

ASJC Scopus subject areas

  • Hematology

Cite this

Treatment outcome of children with acute lymphoblastic leukemia : the Tokyo Children’s Cancer Study Group (TCCSG) Study L04-16. / Takahashi, Hiroyuki; Kajiwara, Ryosuke; Kato, Motohiro; Hasegawa, Daisuke; Tomizawa, Daisuke; Noguchi, Yasushi; Koike, Kazutoshi; Toyama, Daisuke; Yabe, Hiromasa; Kajiwara, Michiko; Fujimura, Junya; Sotomatsu, Manabu; Ota, Setsuo; Maeda, Miho; Goto, Hiroaki; Kato, Yoko; Mori, Tetsuya; Inukai, Takeshi; Shimada, Hiroyuki; Fukushima, Keitaro; Ogawa, Chitose; Makimoto, Atsushi; Fukushima, Takashi; Ohki, Kentaro; Koh, Katsuyoshi; Kiyokawa, Nobutaka; Manabe, Atsushi; Ohara, Akira.

In: International Journal of Hematology, Vol. 108, No. 1, 01.07.2018, p. 98-108.

Research output: Contribution to journalArticle

Takahashi, H, Kajiwara, R, Kato, M, Hasegawa, D, Tomizawa, D, Noguchi, Y, Koike, K, Toyama, D, Yabe, H, Kajiwara, M, Fujimura, J, Sotomatsu, M, Ota, S, Maeda, M, Goto, H, Kato, Y, Mori, T, Inukai, T, Shimada, H, Fukushima, K, Ogawa, C, Makimoto, A, Fukushima, T, Ohki, K, Koh, K, Kiyokawa, N, Manabe, A & Ohara, A 2018, 'Treatment outcome of children with acute lymphoblastic leukemia: the Tokyo Children’s Cancer Study Group (TCCSG) Study L04-16', International Journal of Hematology, vol. 108, no. 1, pp. 98-108. https://doi.org/10.1007/s12185-018-2440-4
Takahashi, Hiroyuki ; Kajiwara, Ryosuke ; Kato, Motohiro ; Hasegawa, Daisuke ; Tomizawa, Daisuke ; Noguchi, Yasushi ; Koike, Kazutoshi ; Toyama, Daisuke ; Yabe, Hiromasa ; Kajiwara, Michiko ; Fujimura, Junya ; Sotomatsu, Manabu ; Ota, Setsuo ; Maeda, Miho ; Goto, Hiroaki ; Kato, Yoko ; Mori, Tetsuya ; Inukai, Takeshi ; Shimada, Hiroyuki ; Fukushima, Keitaro ; Ogawa, Chitose ; Makimoto, Atsushi ; Fukushima, Takashi ; Ohki, Kentaro ; Koh, Katsuyoshi ; Kiyokawa, Nobutaka ; Manabe, Atsushi ; Ohara, Akira. / Treatment outcome of children with acute lymphoblastic leukemia : the Tokyo Children’s Cancer Study Group (TCCSG) Study L04-16. In: International Journal of Hematology. 2018 ; Vol. 108, No. 1. pp. 98-108.
@article{a683ae9f70354a07911755e6aca9560c,
title = "Treatment outcome of children with acute lymphoblastic leukemia: the Tokyo Children’s Cancer Study Group (TCCSG) Study L04-16",
abstract = "The survival rate of children with acute lymphoblastic leukemia (ALL) has increased to approximately 90{\%} after substantial progress in risk-oriented treatment strategies. Between 2005 and 2013, the Tokyo Children’s Cancer Study Group (TCCSG) conducted a risk-oriented, non-randomized study, L04-16. The principal aim of this study was to assemble background characteristics and treatment outcomes, and gather genetic information on leukemic cells under central diagnosis. This report outlines the background characteristics and treatment outcomes of 1033 children with ALL treated according to a TCCSG platform. The 5-year event-free and overall survival (OS) rates for all children were 78.1 ± 1.3 and 89.6 ± 1.0{\%}, respectively. The OS rate was significantly higher in children with B-cell precursor (BCP)-ALL (91.9 ± 1.0{\%}, n = 916) than in those with T-ALL (71.9 ± 4.3{\%}, n = 117, p < 0.001). In univariate analysis for BCP-ALL, children aged 1–6 years (5y-OS: 94.2 ± 1.0{\%}), with an initial white blood cell count of < 20,000/μL (94.0 ± 1.0{\%}), high hyperdiploidy (95.4 ± 1.6{\%}), ETV6-RUNX1 (97.4 ± 1.2{\%}) or TCF3-PBX1 (96.9 ± 2.1{\%}), and “Day8NoBlasts” (96.4 ± 1.1{\%}) had the best outcomes. Genetic investigation revealed two novel fusion genes within this cohort: ETV6-ZNF385A and ZNF362-TCF4. Our study highlighted the clinical aspects of genomic features of ALL in Japanese children. We provide fundamental information for the further molecular investigation of this disease.",
keywords = "Acute lymphoblastic leukemia, Childhood leukemia, Clinical trial, Novel fusion genes",
author = "Hiroyuki Takahashi and Ryosuke Kajiwara and Motohiro Kato and Daisuke Hasegawa and Daisuke Tomizawa and Yasushi Noguchi and Kazutoshi Koike and Daisuke Toyama and Hiromasa Yabe and Michiko Kajiwara and Junya Fujimura and Manabu Sotomatsu and Setsuo Ota and Miho Maeda and Hiroaki Goto and Yoko Kato and Tetsuya Mori and Takeshi Inukai and Hiroyuki Shimada and Keitaro Fukushima and Chitose Ogawa and Atsushi Makimoto and Takashi Fukushima and Kentaro Ohki and Katsuyoshi Koh and Nobutaka Kiyokawa and Atsushi Manabe and Akira Ohara",
year = "2018",
month = "7",
day = "1",
doi = "10.1007/s12185-018-2440-4",
language = "English",
volume = "108",
pages = "98--108",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",
number = "1",

}

TY - JOUR

T1 - Treatment outcome of children with acute lymphoblastic leukemia

T2 - the Tokyo Children’s Cancer Study Group (TCCSG) Study L04-16

AU - Takahashi, Hiroyuki

AU - Kajiwara, Ryosuke

AU - Kato, Motohiro

AU - Hasegawa, Daisuke

AU - Tomizawa, Daisuke

AU - Noguchi, Yasushi

AU - Koike, Kazutoshi

AU - Toyama, Daisuke

AU - Yabe, Hiromasa

AU - Kajiwara, Michiko

AU - Fujimura, Junya

AU - Sotomatsu, Manabu

AU - Ota, Setsuo

AU - Maeda, Miho

AU - Goto, Hiroaki

AU - Kato, Yoko

AU - Mori, Tetsuya

AU - Inukai, Takeshi

AU - Shimada, Hiroyuki

AU - Fukushima, Keitaro

AU - Ogawa, Chitose

AU - Makimoto, Atsushi

AU - Fukushima, Takashi

AU - Ohki, Kentaro

AU - Koh, Katsuyoshi

AU - Kiyokawa, Nobutaka

AU - Manabe, Atsushi

AU - Ohara, Akira

PY - 2018/7/1

Y1 - 2018/7/1

N2 - The survival rate of children with acute lymphoblastic leukemia (ALL) has increased to approximately 90% after substantial progress in risk-oriented treatment strategies. Between 2005 and 2013, the Tokyo Children’s Cancer Study Group (TCCSG) conducted a risk-oriented, non-randomized study, L04-16. The principal aim of this study was to assemble background characteristics and treatment outcomes, and gather genetic information on leukemic cells under central diagnosis. This report outlines the background characteristics and treatment outcomes of 1033 children with ALL treated according to a TCCSG platform. The 5-year event-free and overall survival (OS) rates for all children were 78.1 ± 1.3 and 89.6 ± 1.0%, respectively. The OS rate was significantly higher in children with B-cell precursor (BCP)-ALL (91.9 ± 1.0%, n = 916) than in those with T-ALL (71.9 ± 4.3%, n = 117, p < 0.001). In univariate analysis for BCP-ALL, children aged 1–6 years (5y-OS: 94.2 ± 1.0%), with an initial white blood cell count of < 20,000/μL (94.0 ± 1.0%), high hyperdiploidy (95.4 ± 1.6%), ETV6-RUNX1 (97.4 ± 1.2%) or TCF3-PBX1 (96.9 ± 2.1%), and “Day8NoBlasts” (96.4 ± 1.1%) had the best outcomes. Genetic investigation revealed two novel fusion genes within this cohort: ETV6-ZNF385A and ZNF362-TCF4. Our study highlighted the clinical aspects of genomic features of ALL in Japanese children. We provide fundamental information for the further molecular investigation of this disease.

AB - The survival rate of children with acute lymphoblastic leukemia (ALL) has increased to approximately 90% after substantial progress in risk-oriented treatment strategies. Between 2005 and 2013, the Tokyo Children’s Cancer Study Group (TCCSG) conducted a risk-oriented, non-randomized study, L04-16. The principal aim of this study was to assemble background characteristics and treatment outcomes, and gather genetic information on leukemic cells under central diagnosis. This report outlines the background characteristics and treatment outcomes of 1033 children with ALL treated according to a TCCSG platform. The 5-year event-free and overall survival (OS) rates for all children were 78.1 ± 1.3 and 89.6 ± 1.0%, respectively. The OS rate was significantly higher in children with B-cell precursor (BCP)-ALL (91.9 ± 1.0%, n = 916) than in those with T-ALL (71.9 ± 4.3%, n = 117, p < 0.001). In univariate analysis for BCP-ALL, children aged 1–6 years (5y-OS: 94.2 ± 1.0%), with an initial white blood cell count of < 20,000/μL (94.0 ± 1.0%), high hyperdiploidy (95.4 ± 1.6%), ETV6-RUNX1 (97.4 ± 1.2%) or TCF3-PBX1 (96.9 ± 2.1%), and “Day8NoBlasts” (96.4 ± 1.1%) had the best outcomes. Genetic investigation revealed two novel fusion genes within this cohort: ETV6-ZNF385A and ZNF362-TCF4. Our study highlighted the clinical aspects of genomic features of ALL in Japanese children. We provide fundamental information for the further molecular investigation of this disease.

KW - Acute lymphoblastic leukemia

KW - Childhood leukemia

KW - Clinical trial

KW - Novel fusion genes

UR - http://www.scopus.com/inward/record.url?scp=85044472364&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044472364&partnerID=8YFLogxK

U2 - 10.1007/s12185-018-2440-4

DO - 10.1007/s12185-018-2440-4

M3 - Article

C2 - 29589281

AN - SCOPUS:85044472364

VL - 108

SP - 98

EP - 108

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 1

ER -